- Abstract:
-
Hydroxychloroquine (HCQ; Plaquenil) is used increasingly in the management of a variety of autoimmune disorders, with well established roles in dermatology and rheumatology and emerging roles in oncology. Hydroxychloroquine has demonstrated a survival benefit in patients with systemic lupus erythematosus; some clinicians advocate its use in all such patients. However Hydroxychloroquine and chloroquine (CQ) have been associated with irreversible visual loss due to retinal toxicity. Hydroxychlo...
Expand abstract - Publication status:
- Published
- Peer review status:
- Peer reviewed
- Version:
- Accepted manuscript
- Publisher:
- Nature Publishing Group Publisher's website
- Journal:
- Eye Journal website
- Volume:
- 31
- Issue:
- 6
- Pages:
- 828-845
- Publication date:
- 2017-03-05
- Acceptance date:
- 2016-08-24
- DOI:
- EISSN:
-
1476-5454
- ISSN:
-
0950-222X
- Pubs id:
-
pubs:685370
- URN:
-
uri:4ffa9df5-3f98-48d3-9dc4-d895deb29d7f
- UUID:
-
uuid:4ffa9df5-3f98-48d3-9dc4-d895deb29d7f
- Local pid:
- pubs:685370
- Language:
- English
- Keywords:
- Copyright holder:
- Royal College of Ophthalmologists
- Copyright date:
- 2017
- Notes:
- © 2017 The Royal College of Ophthalmologists
Journal article
Hydroxychloroquine retinopathy.
Actions
Authors
Bibliographic Details
Item Description
Terms of use
Metrics
Altmetrics
Dimensions
If you are the owner of this record, you can report an update to it here: Report update to this record